TG Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/27/2023
TG Therapeutics Stock Forecast and Price Target
The average price target for TG Therapeutics's stock set by recognized analysts recently is $19.00, which would result in a potential downside of approximately -30.15% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $4.00.
-30.15% Downside
TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
TG Therapeutics's Price has grown In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $25.96 – an increase of 100.00%. For the next nine years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.
TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030
TG Therapeutics's Revenue has grown In the last three years, rising from $150.00k to $2.79M – a growth of 1760.00%. In the next year, analysts believe that Revenue will reach $3.18M – an increase of 14.01%. For the next eight years, experts predict that TG Therapeutics's Revenue will grow at a rate of 47.88%.
.jpg)
TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-312.54T – an increase of 235100697.35%. 0 analysts predict TG Therapeutics's Free Cash Flow will decrease by 55.18% in the next year, reaching $-140.07T. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 42.71%, to $-179.05T.
TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's Net Income has grown by 14.73%, rising from $-172.87M to $-198.34M. For the next year, analysts predict that Net Income will reach $-210.01M – an increase of 5.88%. Over the next eight years, experts believe that TG Therapeutics's Net Income will grow at a rate of 30.51%.
TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-188.14M. This represents a growth of 11.35%. Analysts predict that TG Therapeutics's EBITDA will increase in the upcoming year, reaching $-203.36M. This would represent an increase of 8.09%. Over the next eight years, experts predict that TG Therapeutics's EBITDA will grow at a rate of 35.25%.
TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030
TG Therapeutics's EBIT has seen growth In the last two years, going from $-169.06M to $-344.77M – a gain of 103.93% In the following year, the 0 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 26.50%, reaching $-253.39M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 21.86%, falling down to $-269.41M.
TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
TG Therapeutics's EPS has grown In the last two years, rising from $-1.96 to $-2.63 – a growth of 34.18%. In the next year, 0 analysts estimate that TG Therapeutics's EPS will decrease by 11.66%, reaching $-2.32. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 10.44%, reaching $-2.36.
.jpg)